Cardiovascular events among 1090 cancer patients treated with sunitinib, interferon, or placebo: A comprehensive adjudicated database analysis demonstrating clinically meaningful reversibility of cardiac events

European Journal of Cancer

Volumn 50, Issue 12, 2014, Pages 2162-2170

  Ewer, Michael S ^a   Suter, Thomas M ^b   Lenihan, Daniel J ^c   Niculescu, Liviu ^d   Breazna, Aurora ^d   Demetri, George D ^e   Motzer, Robert J ^f  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF BERN   (Switzerland)

^c VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^d Pfizer Ltd   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

^f MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Cancer treatment related hypertension; Cardiotoxicity; Reversibility of cardiotoxic events; Sunitinib

Indexed keywords

ALPHA INTERFERON; PLACEBO; SUNITINIB;

ARTERIAL THROMBOEMBOLISM; ARTICLE; CANCER PATIENT; CARDIOLOGIST; CARDIOVASCULAR RISK; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FAMILY HISTORY; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPERTENSION; INCIDENCE; MAJOR CLINICAL STUDY; ONCOLOGIST; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; VENOUS THROMBOEMBOLISM;

CANCER TREATMENT-RELATED HYPERTENSION; CARDIOTOXICITY; REVERSIBILITY OF CARDIOTOXIC EVENTS; SUNITINIB;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; CARDIOVASCULAR DISEASES; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; HYPERTENSION; INCIDENCE; INDOLES; INTERFERON-ALPHA; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; NEOPLASMS; PYRROLES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 84904070535     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2014.05.013     Document Type: Article

References (23)

1. GlaxoSmithKline. VOTRIENT (pazopanib) prescribing information. Available from URL: https://www.gsksource.com/gskprm/htdocs/documents/VOTRIENT-PI-MG.PDF; 2012 [accessed 02.10.12].
2. Genentech, Inc. AVASTIN® (bevacizumab) prescribing information. Available from URL: http://www.gene.com/gene/products/information/pdf/avastin- prescribing.pdf; 2012 [accessed 01.10.12].
3. Bayer HealthCare Pharmaceuticals, Inc. NEXAVAR (sorafenib) prescribing information. Available from URL: http://berlex.bayerhealthcare.com/html/ products/pi/Nexavar-PI.pdf; 2012 [accessed 01.10.12].
4. Pfizer Inc. SUTENT® (sunitinib malate) prescribing information. Available from URL: http://labeling.pfizer.com/ShowLabeling.aspx?id=607; 2012 [accessed 02.10.12].
5. G. Di Lorenzo, R. Autorino, and G. Bruni et al. Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis Ann Oncol 20 2009 1535 1542
6. T.F. Chu, M.A. Rupnick, and R. Kerkela et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib Lancet 370 2007 2011 2019
7. A.Y. Khakoo, C.M. Kassiotis, and N. Tannir et al. Heart failure associated with sunitinib malate: a multitargeted receptor tyrosine kinase inhibitor Cancer 112 2008 2500 2508
8. R.J. Motzer, T.E. Hutson, and P. Tomczak et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma N Engl J Med 356 2007 115 1124
9. R.J. Motzer, T.E. Hutson, and P. Tomczak et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma J Clin Oncol 27 2009 3584 3590
10. G.D. Demetri, A.T. van Oosterom, and C.R. Garrett et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumor after failure of imatinib: a randomised controlled trial Lancet 368 2006 1329 1338
11. G.D. Demetri, C.R. Garrett, and P. Schöffski et al. Complete longitudinal analyses of the randomized, placebo-controlled, phase III trial of sunitinib in patients with gastrointestinal stromal tumor following imatinib failure Clin Cancer Res 18 2012 3170 3179
12. M.S. Ewer, and S. Lipmann Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity J Clin Oncol 23 2005 2900 2902
13. I.C. Marschner, D. Colquhoun, and R.J. Simes et al. Long-term risk stratification for survivors of acute coronary syndromes. Results from the Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Study J Am Coll Cardiol 38 2001 56 63
14. B.I. Rini, D.P. Cohen, and D.R. Lu et al. Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib J Natl Cancer Inst 103 2011 763 773
15. S. George, P. Reichardt, T. Lechner, S. Li, D.P. Cohen, and G.D. Demetri Hypertension as a potential biomarker of efficacy in patients with gastrointestinal stromal tumor treated with sunitinib Ann Oncol 2012 [Epub ahead of print]
16. M. Schmidinger, C.C. Zielinski, and U.M. Vogl et al. Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma J Clin Oncol 26 2008 5204 5212
17. B.E. Houk, C.L. Bello, B. Poland, L.S. Rosen, G.D. Demetri, and R.J. Motzer Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis Cancer Chemother Pharmacol 66 2010 357 371
18. M.L. Maitland, G.L. Bakris, and H.R. Black et al. Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors J Natl Cancer Inst 102 2010 596 604
19. M.S. Copur, and A. Obermiller An algorithm for the management of hypertension in the setting of vascular endothelial growth factor signaling inhibition Clin Colorectal Cancer 10 2011 151 156
20. Novartis Pharmaceuticals Corp. GLEEVEC (imatinib mesylate) prescribing information. Available from URL: http://www.pharma.us.novartis.com/product/pi/ pdf/gleevec-tabs.pdf; 2012 [accessed 01.10.12].
21. Roche Pharmaceuticals. ROFERON-α (interferon alfa-2a, recombinant) prescribing information. Available from URL: http://www.gene.com/gene/products/ information/roferon-a/pdf/pi.pdf; 2008 [accessed 02.10.12].
22. M.S. Ewer, and D.J. Lenihan Left ventricular ejection fraction and cardiotoxicity: is our ear really to the ground? J Clin Oncol 26 2008 1201 1203
23. M.H. Chen Cardiac dysfunction induced by novel targeted anticancer therapy: an emerging issue Curr Cardiol Rep 11 2009 167 174